U.S. Cellular Therapy for CHF & AFib A patent is legal proof that a process is new, useful, and clearly defined. Kaorta® applies a protected cellular therapy process to congestive heart failure and AFib care, using patient-derived cells prepared for IV infusion within a defined treatment protocol.
Kaorta® is focused on adults exploring cellular therapy for congestive heart failure and AFib. The patented process supports a heart-focused treatment pathway for patients dealing with symptoms such as shortness of breath, limited activity, and rhythm-related concerns.
A medical patent confirms that a process is new, useful, and clearly defined. Kaorta® holds patent protection for a cellular therapy process focused on congestive heart failure and AFib. This matters because patients are choosing a defined treatment protocol, not a copied process or broad marketing claim.
Reviewed and approved by the United States Patent and Trademark Office (USPTO). Covers the entire United States.
Reviewed and approved by the European Patent Office (EPO), covering protection across E.U. member states.
Reviewed and approved by the Canadian Intellectual Property Office (CIPO), providing protection across Canada.
Set up a consult and review the treatment schedule, travel plans and next steps.
Loading Contact Form...
